Alterity Therapeutics (ATHE) Director Peter Marks Buys 47,620 Shares

What Happened Peter Marks (listed on the filing as Marks, Peter Ashley), a director of Alterity Therapeutics (ATHE), reported an open-market/private purchase of 47,620 shares at $0.50 each on 2026-08-31 for $23,810. The same filing also shows a simultaneous reported disposition of a derivative instrument tied to 47,620 shares at $0.50 (value $23,810). The direct purchase is a straightforward acquisition; the derivative disposition is a separate transaction and does not necessarily reflect a sale of the exact shares just purchased.

Key Details

• Transaction date: 2026-08-31; Price: $0.50 per share.
• Acquired: 47,620 shares (purchase) — total cost $23,810.
• Disposed (derivative): 47,620 shares (reported as a derivative transaction) — value $23,810.
• Shares owned after transaction: not provided in the information supplied.
• Filing timeliness: Report filed 2026-09-08 for a 2026-08-31 transaction (marked late). Late Form 4s reduce timely transparency and can attract SEC attention or penalties.
• Transaction codes: P = purchase; the second P entry is listed as a derivative disposition (not a straightforward open-market sale of underlying shares).

Context Derivative transactions can reflect exercises, conversions, offsets, or transfers of instruments tied to shares and don’t always mean the insider sold underlying stock into the market. Because both a purchase and a derivative disposition for the same number of shares and price were reported on the same date, the net economic effect isn’t clear from the filing alone. No 10% ownership or other executive-resignation notes were indicated in the provided data.